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The IL-1 family member IL-38 (IL1F10) suppresses inflammatory and autoimmune con-
ditions. Here, we report that plasma concentrations of IL-38 in 288 healthy Europeans
correlate positively with circulating memory B cells and plasmablasts. IL-38 correlated
negatively with age (p = 0.02) and was stable in 48 subjects for 1 year. In comparison with
primary keratinocytes, IL1F10 expression in CD19+ B cells from PBMC was lower, whereas
cell-associated IL-38 expression was comparable. In vitro, IL-38 is released from CD19+
B cells after stimulation with rituximab. Intravenous LPS in humans failed to induce cir-
culating IL-38, compared to 100-fold induction of IL-6 and IL-1 receptor antagonist. In a
cohort of 296 subjects with body mass index > 27 at high risk for cardiovascular disease,
IL-38 plasma concentrations were significantly lower than in healthy subjects (p< 0.0001),
and lowest in those with metabolic syndrome (p < 0.05). IL-38 also correlated inversely
with high sensitivity C-reactive protein (p < 0.01), IL-6, IL-1Ra, and leptin (p < 0.05). We
conclude that a relative deficiency of the B cell product IL-38 is associated with increased
systemic inflammation in aging, cardiovascular and metabolic disease, and is consistent
with IL-38 as an anti-inflammatory cytokine.
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Introduction
Interleukin 38 (IL1F10) was discovered in silico in 2001, was ini-
tially termed IL-1HY2, and subsequently assigned IL1F10 [1, 2].
The IL1F10 gene is located on chromosome 2 between two recep-
tor antagonists of the IL-1 family, IL-1RN and IL-36RN, with which
it shares protein sequence homologies of 41% and 43%, respec-
tively [1].
IL-38 binds to the IL-36 receptor (IL-1R6) and exhibits anti-
inflammatory properties, for example by reducing the Candida
albicans induced T helper (Th) 17 response in peripheral blood
mononuclear cells (PBMC) and by reducing inflammation, IL-1β,
and IL-6 in murine models of arthritis [3, 4]. Furthermore, IL-
38 can inhibit the induction of IL-6 and IL-8 from LPS-stimulated
PBMC and macrophages [5–7]. In vivo, IL-38 dampens the Th17
response and attenuates inflammation in murine models of psori-
asis, and IL-38-deficient mice show an exacerbated Th17 response
[8].
Mora et al. demonstrated that recombinant IL-38 also binds to
IL-1R9 on macrophages to inhibit IL-6 secretion through restrain-
ing JNK induction and reducing AP1 and NFκB activity [6]. Fur-
thermore, IL-38 can inhibit the IL-1R9 on γδ-T cells and thereby
reduce the Th17 response in mice [8]. IL-1R9 is located on the X-
chromosome and crucial for the development of cognition [9].
Boys with mutations in IL-1R9 suffer from mental retardation
and autism [10]. More recently, the function of IL-38 has gained
interest in the context of inflammatory and autoimmune dis-
eases such as rheumatoid arthritis, psoriasis, systemic lupus ery-
thematosus, Crohn’s disease, primary Sjögren syndrome, hepati-
tis, hidradenitis suppurativa and gestational diabetes, along with
asthma, retinopathy, ST-elevated myocardial infarction (STEMI),
coronary artery disease, cancer, and sepsis [5, 7, 11–21]. SNPs
associated with IL1F10 are associated with serum C-reactive pro-
tein (CRP) concentrations in a genome-wide association study
[22], and recombinant IL-38 inhibits CRP and IL-1β production
by PBMC from patients with hyperlipidemia [20]. Taken together,
IL-38 functions as a suppressor of inflammatory diseases.
To date, little information is available on the cellular source(s)
of circulating IL-38. Also, there are no large-scale studies on cir-
culating IL-38 concentrations either in healthy or overweight sub-
jects, or in association with systemic markers of inflammation,
particularly in overweight subjects at risk for cardiovascular dis-
ease (CVD). Here, we have assessed the source of IL-38 and its
correlations with systemic markers of inflammation.
Results
Circulating IL-38 in healthy subjects
We measured resting circulating IL-38 in a cohort of 288 healthy
subjects. Plasma IL-38 concentrations were detectable in 72% of
119 male and in 64% of 169 healthy female subjects (Fig. 1A,
p = 0.09). As shown in Fig. 1B, IL-38 concentrations were sta-
ble over the course of four seasons in 48 healthy subjects from
the healthy cohort, and each sample correlated with the yearly
average of that subject (all visits p < 0.0001). In addition, IL-38
concentrations were consistently detectable in four out of four vis-
its for 65% of the subjects and consistently undetectable for 17%
of the subjects.
IL-38 concentrations correlated inversely with age (Spearman
r = −0.14, 95%CI −0.26 to −0.02, p = 0.02). No correlation was
found between IL-38 concentrations and body mass index (BMI).
We also found that IL-38 concentrations did not correlate with
circulating IL-1β, IL-1Ra, IL-6, IL-10, IL-18, IL-18BP, TNF-α, alpha-
1-antitrypsin (AAT), resistin, leptin, or adiponectin in healthy sub-
jects (Supporting Information Table S1).
IL-38 in overweight individuals at risk for
cardiovascular disease
We next studied IL-38 concentrations in a cohort of 296 over-
weight subjects at risk for cardiovascular events. The subjects
were more than 55 years old with a BMI of > 27 kg/m2, of which
54% had metabolic syndrome based on the NCEP-ATP III crite-
ria [23], 54% had carotid artery plaques as determined by ultra-
sound, and 56% had hypertension [24]. Incomparison, the sub-
jects of the healthy cohort had a mean BMI of 22.2 ± 3. First, we
observed that IL-38 was detectable in 49% of 165 males and in
39% of 131 females, and that there was no significant difference
between males and females (p = 0.07) (Fig. 1C). In comparison
to the healthy cohort, IL-38 concentrations were on average 3.3-
fold lower in overweight male subjects and 3.1-fold lower in over-
weight female subjects (p < 0.0001). It should be noted that on
average, the overweight cohort was older than the healthy cohort
(mean age 29 ± 5 vs. 67 ± 14, p < .0001).
Overweight individuals with metabolic syndrome often exhibit
a pro-inflammatory state, in which circulating mediators serve as
biomarkers for CVD. As shown in Fig. 1D, overweight individu-
als with metabolic syndrome have significantly lower concentra-
tions of IL-38 than overweight individuals without metabolic syn-
drome (p < 0.05). We also observed that IL-38 concentrations in
the overweight cohort correlated negatively with high sensitivity
(hs)CRP (p < 0.01), leptin, IL-6, and IL-1Ra (all p < 0.05) (Table 1
and Supporting Information Fig. S1). Also, while IL-1β concentra-
tions correlated negatively with IL-38, this relationship did not
reach statistical significance (p = 0.08). IL-38 concentrations did
not correlate with VEGF, adiponectin, IL-18BP, IL-18, resistin, or
AAT in overweight subjects.
Circulating IL-38 concentrations in experimental
human endotoxemia
Human experimental endotoxemia provides a model of sterile
systemic inflammation, in which the kinetics of circulating
immune mediators can be observed [25]. To investigate the
kinetics of IL-38 in experimental human endotoxemia, plasma
IL-38 concentrations were measured before and after a bolus
injection of LPS. As shown in Fig. 2, plasma IL-38 concentra-
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Figure 1. Level of IL-38 in healthy subjects. (A) Mean ± SEM of plasma IL-38 concentrations in 119 male and 169 female healthy subjects of the
healthy cohort. Shown separately by sex is the percentage of subjects with levels above the lower limit of quantitation (16 pg/mL). (B) Mean ± SEM
of plasma IL-38 concentrations in 48 healthy subjects (61% male) in samples collected at four visits at 3-month intervals over the course of 1 year.
(C) Mean ± SEM of plasma IL-38 concentrations in 165 male and 131 female of the overweight cohort. Shown separately by sex is the percent-
age of subjects with levels above the lower limit of quantification (16 pg/mL). (D) Mean ± SEM of plasma IL-38 concentrations in the overweight
cohort divided by metabolic syndrome status. Per cohort, IL-38 concentrations were measured in one experiment by ELISA. Statistical analysis was
performed using the Mann–Whitney test, *p < 0.05.
Table 1. Plasma IL-38 correlates inversely with systemic mediators of
inflammation in overweight subjects
Plasma IL-38
correlation with Spearman r (95% CI) p value
hsCRP −0.16 (−0.27 to –0.04) 0.008
Leptin −0.13 (−0.25 to –0.01) 0.024
IL-6 −0.12 (−0.23 to 0.001) 0.045
IL-1Ra −0.12 (−0.23 to 0.003) 0.049
IL-1β −0.10 (−0.22 to 0.01) 0.076
VEGF −0.06 (−0.17 to 0.06) 0.338
Adiponectin −0.048 (−0.17 to 0.07) 0.414
IL-18Bp −0.04 (−0.16 to 0.07) 0.444
IL-18 −0.04 (−0.16 to 0.08) 0.500
Resistin −0.03 (−0.15to 0.09) 0.579
Alpha-1 antitrypsin 0.01 (−0.11 to 0.13) 0.848
Plasma IL-38 correlates with circulating markers of inflammation in a
cohort of 296 overweight individuals at risk for cardiovascular disease.
Each cytokine was measured during a single ELISA using aliquotted
samples. Shown are the Spearman correlations including the 95% con-
fidence interval and the respective p value.
Figure 2. Cytokine analysis in human experimental endotoxemia.
Comparison of plasma IL-38, IL-1Ra, IL-8, TNF-α, IL-10, and IL-6 con-
centrations at indicated time points before and after administration of
2 ng/kg E. coli LPS (T = 0 minutes) in a model of human experimental
endotoxemia in healthy subjects. IL-38 was measured by ELISA and the
other cytokines by a simultaneous Luminex assay. Data from individual
experiments (N = 10) were pooled and the data were presented asmean
± SEM.
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Table 2. Plasma IL-38 is associated with several B cell subsets in healthy volunteers
Plasma IL-38 correlation with Spearman r (95% CI) p value
Plasmablast/cell (IgM+ CD38++ CD27+) 0.21 (0.06 to 0.34) 0.004
IgM only CD27− (IgD− IgM+ CD27−) 0.19 (0.05 to 0.33) 0.007
IgM only (IgD− IgM+) 0.18 (0.04 to 0.32) 0.011
IgM only memory (IgD− IgM+ CD27) 0.15 (0.01 to 0.29) 0.044
Plasmablast (IgD− IgM− CD38++) 0.18 (0.03 to 0.32) 0.014
Plasmablast/cell (CD19+ CD20−) 0.15 (0.007 to 0.29) 0.035
NKT cell (CD3+ CD56+) −0.17 (−0.31 to −0.02) 0.016
Plasma concentrations of IL-38 are associated with a B cell phenotype. IL-38 concentrations in 190 healthy subjects from the healthy cohort were
measured by ELISA and associated with immune cell subsets measured by flow cytometry in the same sample. Immune cell subsets were analyzed
in freshly obtained samples and IL-38 concentrationswere determined by a single ELISA using aliquotted plasma samples. Shown are the Spearman
correlations including the 95% confidence interval and the respective p value. Circulating leukocyte data were previously published and re-analyzed
for correlations with plasma IL-38 concentrations with permission from Aguirre-Gamboa et al. [42].
tions did not change after LPS infusion, whereas IL-1Ra, IL-8,
TNF-α, IL-10, and IL-6 were induced severalfold by LPS. As
shown in the Supporting Information Table S2, baseline IL-38
concentrations did not correlate with the fold increase or area
under the curve of LPS-induced IL-1Ra, IL-6, IL-8, IL-10, TNF-α,
MIP-1α, MIP-1β, and MCP-1, which were induced by LPS between
sevenfold and 497-fold on average. We conclude that concen-
trations of IL-38 neither change nor predict changes of other
circulating mediators of inflammation in experimental human
endotoxemia.
Circulating IL-38 concentration correlates with B cell
surface markers
After determining circulating concentrations of IL-38 in healthy
subjects as well as in subjects at risk for CVD, we examined the
cellular source of circulating IL-38. We compared IL-38 concentra-
tions at the time of blood sampling from healthy subjects at rest
to the expression of cell surface markers on circulating cells by
flow cytometry. Detectable IL-38 plasma concentrations and abso-
lute circulating cell counts were available for 190 subjects of the
healthy cohort. As shown in Table 2, IL-38 plasma concentrations
correlated positively with absolute numbers of several B cell sub-
sets, most notably memory B cells and plasmablasts (p < 0.05).
In contrast, IL-38 plasma concentrations correlated inversely with
natural killer T (NKT) cells (p < 0.05). The significant correla-
tions are shown in Supporting Information Fig. 2, and a list of
all the cell subsets that were studied can be found in Supporting
Information Table S3.
Isolated B cells from PBMC express IL-38 and produce
IL-38 in vitro
The gene expression of IL1F10 has been detected in PBMC of
STEMI and hyperlipidemia patients [14, 20]. We next addressed
the issue of IL1F10 expression by PBMC from healthy subjects.
We demonstrate that IL1F10 gene expression was detectable in
isolated CD19+ B cells from PBMC, while it was not detectable
in PBMC depleted of CD19+ B cells (Fig. 3A). As a positive con-
trol for IL1F10 expression, we analyzed human keratinocytes that
were undifferentiated, overconfluent, or terminally differentiated.
The keratinocyte samples expressed IL1F10 mRNA fourfold to 12-
fold higher than isolated CD19+ B cells from PBMC (p < 0.05).
As shown in Fig. 3B, protein concentrations of IL-38 were only
detectable in lysates from CD19+ PBMC and not total PBMC or
CD19+ depleted PBMC (p < 0.01). IL-38 protein levels were sim-
ilar in lysates of keratinocytes and isolated B cells, indicating that
IL1F10 mRNA expression does not necessarily correlate with IL-
38 protein concentrations. In the supernatants of CD19+ B cells,
but not PBMC depleted of CD19+ B cells, IL-38 was present after
24 and 48 h stimulation with rituximab, an anti-CD20 antibody
(Fig. 3C).
Discussion
This is the first study to examine circulating IL-38 concentrations
in large cohorts of humans during healthy and inflammatory con-
ditions. We measured IL-38 concentrations in plasma of 288 ran-
domly selected individuals who were part of a larger 500 subject
cohort of healthy subjects [26, 27]. IL-38 concentrations were
detectable (> 16 pg/mL) in 72% of men and 64% of women,
and although the difference was not statistically significant (p =
0.09), the data indicate a trend toward higher concentrations in
men. Furthermore, IL-38 concentrations were stable in a subset
of 48 healthy subjects over four seasons. We also compared IL-
38 concentrations with the concentrations of other cytokines and
mediators previously measured in this healthy cohort [27]. For
example, in these subjects myeloid-derived IL-1β, IL-6, and IL-
1Ra each correlate with one another, and IL-1β correlate inversely
with the hepatic serine protease inhibitor AAT, an endogenous
inhibitor of inflammation [27, 28]. However, as a B cell product,
IL-38 did not correlate with circulating IL-1β, IL-1Ra, IL-6, IL-18,
IL-18BP, VEGF, AAT, resistin, leptin, or adiponectin. We observed
that IL-38 concentrations negatively correlated with age, whereas
IL-6, IL-1Ra, and IL-18BP increased with age [27]. BMI positively
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Figure 3. IL-38 expression in PBMC and keratinocytes. (A) IL1F10 and GAPDH mRNA expression was detected by RT-qPCR in keratinocyte cultures
that were either undifferentiated, overconfluent, or terminally differentiated, as well as resting PBMC isolated from venous blood, isolated CD19+
B cells from these PBMC, and the CD19+ depleted flow-through. Expression of IL1F10 was normalized to GAPDH using the 2−Ct method. (B) IL-38
protein expression was measured in cell lysates by ELISA and expressed as pg IL-38 per mg total protein. (C) IL-38 protein in the supernatant of
CD19+ enriched or depleted PBMC after 24 h and 48 h stimulation with rituximab and measured by ELISA. Data are expressed as mean ± SEM from
three independent experiments with a total of three donors of keratinocytes and PBMC that were analyzed in parallel by RT-qPCR and ELISA. N.d.:
not detected. Unpaired T test, *p < 0.05, **p < 0.01.
correlated with plasma concentrations of IL-1Ra, IL-18, IL-6, lep-
tin, and hsCRP [27], but not with IL-38. We conclude that IL-38
concentrations do not correlate with myeloid-derived cytokines in
healthy subjects.
Next, we investigated plasma IL-38 concentrations in a cohort
of overweight subjects that are in a state of chronic, low-grade
inflammation, and at increased risk of a cardiovascular event
[24]. First, we found that IL-38 concentrations were signifi-
cantly lower in overweight individuals compared to healthy vol-
unteers. Relevant to CVD risk, IL-38 concentrations were lower
in subjects with high concentrations of circulating hsCRP. As
the Canakinumab Anti-inflammatory Thrombosis Outcome Study
[29] of 10 061 similarly overweight subjects with hsCRP > 2 mg/L
has shown that treament with the IL-1β neutralizing antibody
canakinumab reduces CVD, we measured plasma IL-1β concentra-
tions in the overweight cohort. We observed higher concentrations
of IL-1β in those subjects with low IL-38, although this correlation
did not reach statistical significance. Since in the healthy cohort
of 500 subjects IL-1β concentrations significantly correlated pos-
itively with IL-6 [27], we investigated the relationship between
IL-38 and IL-6 in the overweight cohort and found a significant
inverse correlation. This inverse relationship of IL-38 with IL-6
is consistent with an anti-inflammatory property of IL-38 [30].
While in healthy subjects IL-1β and IL-6 correlate, and IL-1β is
known to induce IL-6, we hypothesize that IL-38 functions to may
suppress IL-1β production. Indeed, we previously observed that
© 2020 The Authors. European Journal of Immunology published by
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recombinant IL-38 suppresses IL-1β in murine models of experi-
mental arthritis [4].
In the overweight cohort, IL-38 concentrations were also lower
in individuals with high concentrations of leptin. Others have
reported that leptin and hsCRP are elevated in individuals with
CVD risk and metabolic syndrome [31]. In our study, IL-38 con-
centrations were lower in overweight individuals with metabolic
syndrome compared to those without metabolic syndrome. Thus,
low concentrations of IL-38 are found in subjects with metabolic
syndrome with high hsCRP and leptin.
There have been several reports on the link between IL-38 and
hsCRP. In patients with acute STEMI, IL-38 plasma concentrations
were elevated concurrently with hsCRP concentrations from the
time of admission until 7 days later [14]. We hypothesize that
chronic low concentrations of IL-38 in overweight individuals are
a biomarker of CVD risk, and that an increase in IL-38 during an
acute cardiovascular event represents a response to limit inflam-
mation and restore homeostasis [14]. In patients with an acute
cardiovascular event, IL-1Ra concentrations are also elevated to
limit inflammation and restore homeostasis [32].
These findings are consistent with lower concentrations of IL-
6, hsCRP, and IL-1β that occur in overweight subjects with higher
concentrations of IL-38, that is, those without metabolic syn-
drome. In patients with hyperlipidemia, IL1F10 mRNA in PBMC
and IL-38 in serum were elevated compared to healthy controls
[20]. PBMC from patients with hyperlipidemia, when treated in
vitro with recombinant IL-38, reduced gene expression and pro-
tein secretion of IL-6, IL-1β, and CRP [20]. In that study, patients
with high serum concentrations of IL-38 were more sensitive
to lipid-lowering therapy with atorvastatin [20]. In mice, over-
expression of Il1f10 resulted in reduced hepatic fat accumula-
tion, liver damage in high-fat diet induced obesityand reduced
adipocyte hypertrophy [33]. Together, human and mouse studies
support the concept that high concentrations of IL-38 are func-
tional in suppressing inflammation, while low concentrations are
a biomarker for cardiovascular and metabolic risk. In acute dis-
ease, plasma IL-38 correlates with CRP in rheumatoid arthritis
patients, and is elevated in comparison to healthy controls [34].
To our knowledge, this is the first study of circulating IL-38 in
a human model of systemic inflammation, in which human volun-
teers receive a single bolus of intravenous LPS. We observed that
IL-38 concentrations were stable after infusion with LPS, whereas
IL-6, IL-8, IL-10, IL-1Ra, TNF-α, MIP-1α, MIP-1β, and MCP1 each
increased several fold, as expected [25]. Plasma concentrations of
IL-38 in this experimental endotoxemia study were comparable to
those detected in the cohort of healthy volunteers. Furthermore,
baseline IL-38 concentrations did not predict the fold change or
area under the curve of other circulating mediators. This is in con-
trast with the observations of Xu et al., who demonstrated that IL-
38 concentrations are elevated in serum from adult and pediatric
sepsis patients compared to healthy controls [19].
Previous reports show that IL1F10 mRNA is predominantly
present in the keratinocytes of the skin, the spleen, and pro-
liferating B cells of the tonsil [2, 15, 35]. In colon biopsies of
inflammatory bowel disease patients, IL1F10 expression was co-
localized completely with a portion of CD19+ B cells, while IL1F10
expression was not detected in CD68+ macrophages or CD3+
T cells [35]. Here, we demonstrate that IL1F10 gene expression
is specific for isolated B cells from PBMC, but not total PBMC
or the flow-through that is depleted of B cells. In these B cells,
IL1F10 mRNA expression is fourfold to 12-fold lower when com-
pared to primary human keratinocytes. Interestingly, B cells can
also express IL-36 family members IL-36α [36] and IL-36γ [37]
and their receptor IL-36R [38], and hence the additional produc-
tion of the IL-36R inhibitor IL-38 by B cells may bring balance to
IL-36 signaling.
After demonstrating that IL1F10 expression is specific to B cells
isolated from PBMC, we sought to relate plasma IL-38 concen-
trations in healthy subjects to the cell subsets that are present
in the same blood sample. In 190 healthy subjects, circulating
concentrations of IL-38 correlated with several B-cell subsets,
most notably memory B cells and plasmablasts. We observed
that circulating B cell numbers and IL-38 concentrations both
decline with age. In fact, of the four large groups of circulat-
ing B cell subsets (immature-, naïve, memory-B lymphocytes, and
plasma cells), only memory B lymphocytes and plasmablasts/cells
decrease with age, both in relative and absolute counts [39]. The
single negative correlation between IL-38 and circulating cell sub-
sets was with NKT cells. NKT cells generally become activated
in pro-inflammatory conditions, further underscoring the anti-
inflammatory nature of IL-38 [40]. Noteworthy is that there was
no correlation between IL-38 concentrations and circulating neu-
trophils, monocytes, or T cells.
We demonstrate that IL-38 is a B cell derived cytokine in
healthy subjects, which is inversely associated with markers of
innate inflammation that are associated with an increased risk for
cardiovascular disease in overweight subjects. Furthermore, a rel-
ative IL-38 deficiency arises with older age, and a clear reduction
of circulating IL-38 is observed in subjects that are overweight,
while IL-38 concentrations are lowest in overweight subjects with
metabolic syndrome. Future studies on the relationship between
IL-38 and the separate components of the metabolic syndrome
would further strengthen these findings.
Materials and methods
Subjects
Participants received detailed printed and oral information and
gave written consent. Inclusion of subjects and experiments
were conducted according to the principles expressed in the
Declaration of Helsinki. The healthy Dutch 500FG cohort was
approved by the Ethical Committee of Radboud University
Medical Center (NL42561.091.12, 2012/550), as well as the
300 Overweight study (NL34462.091.10). The “Remote Ischemic
Preconditioning on Inflammation During Human Endotoxemia”
(RISPENDO) trial was approved (NL53584.091.15). Plasma
and clinical data in the present study were derived from the
© 2020 The Authors. European Journal of Immunology published by
Wiley-VCH GmbH
www.eji-journal.eu
668 Dennis M. de Graaf et al. Eur. J. Immunol. 2021. 51: 662–671
healthy cohort [27], the overweight cohort [24], and the human
endotoxemia trial [41]. The studies on healthy and overweight
subjects are part of the Human Functional Genomics Project
(HFGP) (www.humanfunctionalgenomics.org).
Healthy subjects
The healthy cohort consists 534 healthy individuals of Cau-
casian origin aged > 18 years, sampled between July 2013
and December 2014 at the Radboud University Medical Cen-
ter, The Netherlands [26, 27, 42]. Exclusion criteria were preg-
nancy/breastfeeding, chronic or acute disease at the time of sam-
pling, and medication use, either prescribed or over the counter,
in the last month before the study. The median age was 23 years
(interquartile range [IQR] 21–27 years) and 56% were female.
The median BMI was 22.2 (20.7–24.4) and 83.1% had a BMI
below 25. 48% of women used an oral contraceptive, and 13.2%
of subjects regularly used tobacco. From the healthy cohort, 288
plasma samples were available for measurement of plasma IL-38
concentrations.
Overweight individuals
The 300 overweight cohort [24] consists of individuals aged
55–80 of European origin with a BMI > 27. Subjects with
a recent cardiovascular event (myocardial ischemia, transient
ischemic attack, stroke <6 months), a history of bariatric surgery
or bowel resection, inflammatory bowel disease, renal dysfunc-
tion, increased bleeding tendency, use of oral or subcutaneous
anti-coagulant therapy, use of thrombocyte aggregation inhibitors
other than acetylsalicylic acid, and carbasalate calcium were
excluded. The presence of metabolic syndrome was diagnosed
using the clinical criteria defined in the National Cholesterol Edu-
cation Program (NCEP-ATP III criteria). The median age was 67
years (IQR 63–71 years) and 45% were female. The median BMI
was 29.9 (28.3–31.9). None of the women used an oral contra-
ceptive and 8.6% of subjects regularly used tobacco. From the
300 overweight cohort, 296 plasma samples were available for
measurement of IL-38 concentrations.
Experimental human endotoxemia
In the RISPENDO trial control group, ten healthy male subjects
were included, aged 22.1 ± 3.1 years, 183 ± 11 cm, weighing
73 ± 7.8 kg, and having a BMI of 21.8 ± 1.8. To achieve a con-
trolled inflammatory state, subjects were pre-hydrated and subse-
quently infused with 2 ng/kg Escherischia coli LPS intravenously
in 1 min at t = 0 h. Blood was collected in EDTA before LPS
infusion (t = −60 and 0), and after 30, 60, 90, 120, 240, and
480 min.
Blood collection and plasma preparation
Venous blood from the healthy, overweight, and RISPENDO
cohorts was collected in EDTA tubes and centrifuged immediately
at 2000 x g for 10 min at 4°C after which the plasma was aliquoted
into smaller volumes and stored at −80°C until analysis.
CD19+ cell isolation, keratinocyte culture, and IL-38
qPCR
Isolation of PBMC was performed as described before [43].
B cells were isolated from PBMCs using MACS CD19 positive
isolation kit (Miltenyi Biotech) according the manufacturer’s pro-
tocol, stained for CD45 and CD19, and > 95% purity was con-
firmed by flow cytometry. From PBMC, isolated CD19+ B cells,
and PBMC depleted in CD19+ B cells, mRNA and protein were
obtained as described below, and IL-38 expression was detected
by RT-qPCR and ELISA. In addition, CD19+-enriched and CD19+-
depleted PBMC were cultured at 100 000 cells/well in 200 μL
RPMI supplemented with pyruvate (0.02 mM), glutamax (2 mM),
penicillin (100 U/mL), streptomycin (100 μg/mL; all from Gibco,
UK), and 10% heat-inactivated pooled human serum [44]. For
stimulation experiments, the cells were cultured with 5 μg/mL
rituximab (Roche, Germany), an anti-CD20 monoclonal antibody,
and IL-38 concentrations were measured by ELISA after 24h and
48h. Human epidermal keratinocytes (Thermo Fisher, Waltham,
MA) were cultured in Epilife medium (Thermo Fisher) supple-
mented with human keratinocyte growth supplement (Thermo
Fisher). Keratinocytes were plated at 1.0 × 105 cells/well in
12-well plate. Undifferentiated keratinocytes were harvested at
100% confluency. Overconfluent keratinocyte harvested 4 days
post 100% confluency. Starting at 90% confluency, differentiated
keratinocytes were generated by first 24 h culture in 1.0 mM Ca2+,
followed by 72 h culture in 1.5 mM Ca2+. mRNA and protein were
obtained as described below, and IL-38 expression was detected
by RT-qPCR and ELISA.
RNA isolation and RT-qPCR
Total RNA from keratinocytes and PBMC was extracted using
an RNeasy Mini Kit (QIAGEN, Venlo, The Netherlands). cDNA
synthesis was performed with iScript cDNA Synthesis Kit (BioRad,
Hercules, CA). cDNA was synthesized as follows: 5 min at 25°C,
20 min at 46°C, and then 1 min at 95°C. PCR amplification and
quantitation were performed using a Power Up SYBR Green
PCR Master Mix (Applied Biosystems, Foster City, CA) on the
AriaMx Real-Time PCR system (Agilent Technologies). PCR was
performed as follows: one cycle 2 min at 50°C, followed by 5
min at 95°C: 40 cycles 5 min at 95°C; gene-specific annealing
temperature 1 min at 60°C: and then 30 s at 95°C, followed by 30
s at 65°C and 30 s at 95°C. Primer sequences for IL-38 are similar
to those used in [15]: forward—5′-AAG GTC CCC ATT TTC CTG
GG-3′; reverse—5′-CTC AAT GTT CAC ATC CTC CAG-3′. GAPDH:
© 2020 The Authors. European Journal of Immunology published by
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forward—5′-TGC ACC ACC AAC TGC TTA GC-3′; reverse—5′-GGC
ATG GAC TGT GGT CAT GAG-3′. Expression of IL1F10 was calcu-
lated as a ratio to GAPDH using the 2−Ct method. In addition,
keratinocyte and PBMC were lysed in RIPA buffer (Sigma) sup-
plemented with protease inhibitors (Roche), and centrifuged at
13 000 x g for 20 min at 4°C. Protein concentrations of the cleared
supernatants were measured by Bio-Rad protein assay (Bio-Rad
Laboratories, Hercules, CA). Cell-associated IL-38 concentrations
were measured by ELISA and expressed as pg/mg total protein.
Cytokine measurements
The human IL-38/IL1F10 DuoSet ELISA (BioTechne, Minneapo-
lis, MN, USA) [19, 45] was used according to the manufacturer’s
instructions, with the exception that the sample was incubated
with the capture antibody in the ELISA plate overnight at 4°C.
Plasma samples and cell culture supernatants were diluted 1:1
in PBS containing 1% BSA (Sigma). A standard curve of 8–2000
pg/mL yielded a lower limit of quantification of 16 pg/mL and
an upper limit of quantification of 4000 pg/mL. Values below the
detection limit were assigned the lower limit of quantification.
To investigate the recovery of IL-38 in the IL-38 Elisa, we added
200 pg/mL IL-38 to plasma and compared this to IL-38 added
to PBS alone. Approximately 55% of the IL-38 that was added
to the plasma was detected, indicating that plasma factors may
influence the detection of IL-38 protein. In the healthy cohort, the
circulating mediators resistin, leptin, adiponectin, CRP, and AAT
were measured in EDTA plasma using DuoSet ELISA (BioTechne)
following the manufacturer’s protocol. Plasma IL-1β, IL-6, IL-18,
VEGF, TNF-α, and IL-10 were measured in Simple Plex cartridges
using the ELLA apparatus (Protein Simple, San Jose, CA). Vitamin
D levels were analyzed by LC-MS as described previously [27]. In
the overweight cohort, AAT, hsCRP, adiponectin, and resistin were
measured by DuoSet ELISA (BioTechne). IL-1β and IL-18 were
measured using Simple Plex cartridges. In the healthy and over-
weight cohorts, IL-1Ra and IL-18 binding protein were measured
by Quantikine ELISA (BioTechne). In samples of the human endo-
toxemia study, TNF-α, IL-1Ra, IL-6, IL-8, IL-10, MIP-1β, MIP-1α,
and MCP-1 were measured using a simultaneous Luminex assay
according to the manufacturer’s instructions (Millipore, Bellerica,
MA, USA).
Flow cytometry of circulating cell subsets
The data on circulating leukocyte subsets were previously pub-
lished, and correlated in this study to plasma IL-38 concentrations
with permission from Aguirre-Gamboa et al. [42]. In short, flow
cytometry was performed within 2–3 h after sample collection
on a 10-color Navios flow cytometer (Beckman Coulter, Fuller-
ton, CA) equipped with three solid-state lasers (488, 638, and
405 nm). Supporting Information Table S3 contains the list of the
CD markers. The purity of CD19+ B cells isolated from PBMC was
confirmed with antibodies to CD19 and CD45. Data were ana-
lyzed using Kaluza software version 1.3 (Beckman Coulter).
Statistical analysis
Correlations and corresponding p-values were calculated using
the Pearson or the rank-based Spearman correlation using Graph-
pad Prism software v7.0 (GraphPad Software). When two param-
eters were compared, the rank-based Mann–Whitney test was
used unless otherwise indicated. All statistical tests were two
sided, and p values < 0.05 were considered significant.
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